IL6 and hepatocellular carcinoma: Besides its oncogenic properties conferred on tumor cells through the JAK/STAT signaling pathway, IL-6 promotes PD-L1 expression in monocytes and macrophages in human HCC, contributing to immunosuppression in patients [114].